LSI Segment Divestment
Full-Year 2020 Corporate Overview
Strong full-year performance, driven by sales growth in LPBN
Lonza delivers on guidance with 12.0%² sales growth, with CHF 4.5 billion sales, and
CHF 1.4 billion CORE EBITDA, resulting in a 31.2% margin
Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as
Specialty Ingredients (LSI) is reported as a discontinued operation
Strong performance in LPBN with 12.2%² sales growth and CORE EBITDA margin of
32.1%, driven by Biologics business
Production of the drug substance for Moderna COVID-19 Vaccine has commenced at
Portsmouth (USA) and Visp (CH) sites
LSI³ delivered a solid performance, with 3.4%² sales growth alongside an improved
CORE EBITDA margin, reported at 20.3%4
Winding road at Faroe
12020 Guidance relates to Lonza Group results without LSI reported as discontinued operations
2 All sales growth figures are at a constant exchange rate (CER)
3 Specialty Ingredients Business (excluding Corporate/carve-out and divestiture costs directly attributable to LSI)
4 CORE EBITDA margin at a constant exchange rate (CER)
CORE definition: See appendix
4View entire presentation